Eric Crown
AbbVie
8 Papers
12 Citations
Eric Crown is an academic researcher from AbbVie. The author has contributed to research in topics: Population & Glecaprevir. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis
Pietro Lampertico,José A. Carrión,Michael P. Curry,Juan Turnes,Markus Cornberg,Francesco Negro,Ashley Brown,Marcello Persico,Nicole Wick,Ariel Porcalla,Andreas Pangerl,Eric Crown,Lois Larsen,Yao Yu,Heiner Wedemeyer +14 more
TL;DR: Real-world evidence indicates that glecaprevir/pibrentasvir is a well-tolerated and highly effective pangenotypic treatment for a broad range of HCV-infected patients.
98
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
Atsushi Naganuma,Kazuaki Chayama,Kazuo Notsumata,Edward Gane,Graham R. Foster,David L. Wyles,Paul Y. Kwo,Eric Crown,Abhi Bhagat,Federico J. Mensa,Tetsuya Otani,Lois Larsen,Margaret Burroughs,Hiromitsu Kumada +13 more
TL;DR: 8-week G/P treatment is safe and efficacious in DAA-naive patients without cirrhosis and with HCV GT1 or GT2 infection, demonstrating high SVR12 rates regardless of baseline patient and disease characteristics.
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Peter Ferenci,Suzanne Bourgeois,Peter Buggisch,Suzanne Norris,Manuela Curescu,Dominique Larrey,Fiona Marra,Henning Kleine,Patrick K. Dorr,Mariem Charafeddine,Eric Crown,Mark Bondin,David Back,Robert Flisiak +13 more
TL;DR: Real‐world evidence confirms the effectiveness of OBV/PTV/r ± DSV ± RBV in patients with HCV GT1 or GT4, regardless of common comorbidities or comedications, and is consistent with clinical trial results.
15
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Philippe J. Zamor,Ashley Brown,Douglas E. Dylla,John F. Dillon,Anne F Luetkemeyer,Jordan J. Feld,David Mutimer,Reem Ghalib,Eric Crown,Sandra S. Lovell,Yiran Hu,Christophe Moreno,David R. Nelson,Massimo Colombo,Georgios Papatheodoridis,Juergen K. Rockstroh,Richard Skoien,Eric Lawitz,Ira M. Jacobson +18 more
TL;DR: In this paper, the authors evaluated the impact of non-adherence on sustained virologic response at post-treatment week 12 (SVR12), factors associated with nonadherence, and efficacy in patients interrupting G/P treatment.
9
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Jeong Heo,Yoon Jun Kim,Jin-Woo Lee,Ji Hoon Kim,Young-Suk Lim,Kwang Hyub Han,Sook-Hyang Jeong,Mong Cho,Ki Tae Yoon,Si Hyun Bae,Eric Crown,Linda M Fredrick,Negar N. Alami,Armen Asatryan,Dohyun Kim,Seung Woon Paik,Youn-Jae Lee +16 more
TL;DR: In this paper, the authors performed an integrated analysis of five phase II and III trials to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection.
4